References:
1. Biancari F, Mikkola R, Heikkinen J, Lahtinen J, Airaksinen KEJ,
Juvonen T. Estimating the risk of complications related to
re-exploration for bleeding after adult cardiac surgery : a systematic
review and meta-analysis. Eur J Cardiothorac Surg .
2012;41(1):50-55. doi:10.1016/j.ejcts.2011.04.023
2. Vivacqua A, Koch CG, Yousuf AM, Nowicki ER, Houghtaling PL,
Blackstone EH, et al. Morbidity of Bleeding After Cardiac Surgery : Is
It Blood Transfusion , Reoperation for Bleeding , or Both? Ann
Thorac Surg . 2011;91(6):1780-1790. doi:10.1016/j.athoracsur.2011.03.105
3. Koch C, Li L, Duncan A, Mihaljevic T, Cosgrove D, Loop F. Morbidity
and mortality risk associated with red blood cell and blood- component
transfusion in isolated coronary artery bypass grafting. Crit Care
Med . 2006;34(6):1608-1616. doi:10.1097/01.CCM.0000217920.48559.D8
4. Schumer EM, Chaney JH, Trivedi JR, Linsky PL, Williams ML, Slaughter
MS. Emergency Coronary Artery Bypass Grafting: Texas Hear Inst J .
2016;43(3):214-219.
5. Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, et
al. AHA Statistical Update Heart Disease and Stroke Statistics — 2016
Update A Report From the American Heart Association. Circulation .
2016;133:38-360. doi:10.1161/CIR.0000000000000350
6. Barnes GD, Lucas E, Alexander GC, Goldberger ZD. National Trends in
Ambulatory Oral Anticoagulant Use. Am J Med .
2019;128(12):1300-1305.e2. doi:10.1016/j.amjmed.2015.05.044
7. Glotzer T, Hellkamp A, Zimmerman J, Sweeney M, Yee R, Marinchak R.
Atrial High Rate Episodes Detected by Pacemaker Diagnostics Predict
Death and Stroke. Circulation . 2003;107:1614-1619.
8. Eikelboom J, Oldgren J, Ph D, Parekh A, Pogue J, Sc M, et al.
Dabigatran versus warfarin in patients with atrial fibrillation. N
Engl J Med . 2009;361(12):1139-1151.
9. Hylek EM, Hanna M, Al-khalidi HR, Ph D, Ansell J, Atar D, et al.
Apixaban versus Warfarin in Patients with Atrial Fibrillation. N
Engl J Med . 2011;365(11):981-992.
10. Wallentin L, Becker R, A B, CP C. Ticagrelor versus clopidegrol in
patients with acute coronary syndrome. N Engl J Med .
2009;361:1045-1057. doi:10.1056/NEJMoa1505949
11. Shih AW, Crowther MA. Reversal of direct oral anticoagulants: a
practical approach. Hematol Am Soc Hematol Educ Progr .
2016;2(1):612-619.
12. Scaglione F. New Oral Anticoagulants: Comparative Pharmacology with
Vitamin K Antagonists. Clin Pharmacokinet . 2013;52(2):69-82.
doi:10.1007/s40262-012-0030-9
13. Antovic JP, Skeppholm M, Eintrei J, Boija EE, Söderblom L, Norberg
E, et al. Evaluation of coagulation assays versus LC-MS / MS for
determinations of dabigatran concentrations in plasma. Eur J Clin
Pharmacol . 2013;69(11):1875-1881. doi:10.1007/s00228-013-1550-4
14. Favaloro E, Bonar R, Butler J, Marsden K. Laboratory testing for the
new oral anticoagulants: a review of current practice. Pathology .
2013;45(4):435-437.
15. Reilly P, Lehr T, Haertter S, Connolly S, Yusuf S, Eikelboom J, et
al. The Effect of Dabigatran Plasma Concentrations and Patient
Characteristics on the Frequency of Ischemic Stroke and Major Bleeding
in Atrial Fibrillation Patients: the RE-LY Trial (Randomized Evaluation
of Long-Term Anticoagulation Therapy). J Am Coll Cardiol .
2014;63(4):321-328. doi:10.1016/j.jacc.2013.07.104
16. Nowak G. The ecarin clotting time, a universal method to quantify
direct thrombin inhibitors. Pathophysiol Haemost Thromb .
2003;33(4):173-183. doi:10.1159/000081505
17. Samuelson BT, Cuker A. Blood Reviews Measurement and reversal of the
direct oral anticoagulants. Blood Rev . 2019;31(1):77-84.
doi:10.1016/j.blre.2016.08.006
18. Seyve L, Richarme C, Polack B, Marlu R. Impact of four direct oral
anticoagulants on rotational thromboelastometry (ROTEM). Int J Lab
Hematol . 2018;40(1):84-93. doi:10.1111/ijlh.12744
19. Zghaibe W, Scheuermann S, Munting K, Blaudszun G, Besser M, Ortmann
E, et al. Clinical utility of the Quantra® point-of-care haemostasis
analyser during urgent cardiac surgery. Anaesthesia .
2020;75(3):366-373. doi:10.1111/anae.14942
20. Tomaselli GF, Mahaffey KW, Cuker A, Dobesh PP, Doherty JU, Eikelboom
JW, et al. 2020 ACC Expert Consensus Decision Pathway on Management of
Bleeding in Patients on Oral Anticoagulants: A Report of the American
College of Cardiology Solution Set Oversight Committee. J Am Coll
Cardiol . 2020;76(5):594-622. doi:10.1016/j.jacc.2020.04.053
21. Grottke O, Aisenberg J, Bernstein R, Goldstein P, Huisman M V,
Jamieson DG, et al. Efficacy of prothrombin complex concentrates for the
emergency reversal of dabigatran-induced anticoagulation. Crit
Care . 2016;20:115. doi:10.1186/s13054-016-1275-8
22. Majeed A, Ågren A, Holmström M, Bruzelius M, Chaireti R, Odeberg J,
et al. Management of rivaroxaban- or apixaban-associated major bleeding
with prothrombin complex concentrates: A cohort study. Blood .
2017;130(15):1706-1712. doi:10.1182/blood-2017-05-782060
23. Goldstein JN, Refaai MA, Jr TJM, Lewis B, Goldberg-alberts R, Hug
BA, et al. Four-factor prothrombin complex concentrate versus plasma for
rapid vitamin K antagonist reversal in patients needing urgent surgical
or invasive interventions : a phase 3b , open-label , non-inferiority ,
randomised trial. Lancet . 2015;385(9982):2077-2087.
doi:10.1016/S0140-6736(14)61685-8
24. Demeyere R, Gillardin S, Arnout J, Strengers PFW. Comparison of
fresh frozen plasma and prothrombin complex concentrate for the reversal
of oral anticoagulants in patients undergoing cardiopulmonary bypass
surgery: a randomized study. Int J Transfus Med .
2010;99(3):251-260. doi:10.1111/j.1423-0410.2010.01339.x
25. Myles PS, Smith JA, Forbes A, Silbert B, Jayarajah M, Painter T, et
al. Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.N Engl J Med . 2017;376(2):136-148. doi:10.1056/nejmoa1606424
26. Cuker A, Burnett A, Triller D, Crowther M, Ansell J, Cott EM Van, et
al. Reversal of direct oral anticoagulants: Guidance from the
Anticoagulation Forum. Am J Hematol . 2019;94(6):697-709.
doi:10.1002/ajh.25475
27. Pollack C, Reilly P, van Ryn J, Eikelboom J, Glund S, Bernstein R.
Idarucizumab for Dabigatran Reversal — Full Cohort Analysis. N
Engl J Med . 2017;377(5):431-441. doi:10.1056/NEJMoa1707278
28. Crespo-leiro MG, Amador RL, Granados L, Barge-caballero SMCDE,
Segovia-cubero J, Rangel-sousa FGD, et al. Use of Idarucizumab to
reverse the anticoagulant effect of dabigatran in cardiac transplant
surgery . A multicentric experience in Spain. Clin Transpl .
2019;33(12):e13748. doi:10.1111/ctr.13748
29. Connolly SJ, Crowther M, Eikelboom JW, Gibson CM, Curnutte JT,
Lawrence JH, et al. Full study report of andexanet alfa for bleeding
associated with factor Xa inhibitors. N Engl J Med .
2019;380(14):1326-1335. doi:10.1056/NEJMoa1814051
30. Schulman S, Gross PL, Ritchie B, Nahirniak S, Lin Y, Lieberman L, et
al. Prothrombin Complex Concentrate for Major Bleeding on Factor Xa
Inhibitors : A Prospective Cohort Study. Thromb Haemost .
2018;118:842-851.
31. Watson CJ, Zettervall S, Hall M, Ganetsky M. Difficult
Intraoperative Heparinization Following Andexanet Alfa Administration.Clin Pract Cases Emerg Med . 2019;3(4):390-394.
doi:10.5811/cpcem.2019.9.43650
32. Flaherty D, Connors JM, Singh S, Sylvester KW, Rimsans J, Cornella
L. Andexanet Alfa for Urgent Reversal of Apixaban Before Aortic Surgery
Requiring Cardiopulmonary Bypass: A Case Report. A&A Pract .
2019;13(7):271-273. doi:10.1213/xaa.0000000000001052
33. Levy JH, Welsby I. Andexanet Alfa Use in Patients Requiring
Cardiopulmonary Bypass: Quo Vadis? A&A Pract .
2019;13(12):477-477. doi:10.1213/xaa.0000000000001115
34. Erdoes G, De Arroyabe B, Bolliger D, Ahmed A, Koster A, Agarwal S,
et al. International consensus statement on the peri-operative
management of direct oral anticoagulants in cardiac surgery.Anaesthesia . 2018;73(12):1535-1545.
35. Parasrampuria DA, Marbury T, Matsushima N, Chen S, Wickremasingha
PK, He L, et al. Pharmacokinetics, safety, and tolerability of edoxaban
in end-stage renal disease subjects undergoing haemodialysis.Thromb Haemost . 2015;113(4):719-727. doi:10.1160/TH14-06-0547
36. Awtry E, Loscalzo J. Aspirin. Circulation .
2000;101(10):1206-1218. doi:10.1097/01.NURSE.0000524762.35753.23
37. Myles PS, Smith JA, Forbes A, Silbert B, Jayarajah M, Painter T, et
al. Stopping vs. continuing aspirin before coronary artery surgery.N Engl J Med . 2016;374(8):728-737. doi:10.1056/NEJMoa1507688
38. Jacob M, Smedira N, Blackstone E, Williams S, Cho L. Effect of
timing of chronic preoperative aspirin discontinuation on morbidity and
mortality in coronary artery bypass surgery. Circulation .
2011;123(6):577-583. doi:10.1161/CIRCULATIONAHA.110.957373
39. Hansson EC, Malm CJ, Hesse C, Björn Hornestam, Dellborg M, Rexius H,
et al. Platelet function recovery after ticagrelor withdrawal in
patients awaiting urgent coronary surgery. Eur J Cardio-thoracic
Surg . 2017;51(4):633-637. doi:10.1093/ejcts/ezw373
40. Hassan K, Kannmacher J, Wohlmuth P, Budde U, Schmoeckel M, Geidel S.
Cytosorb Adsorption During Emergency Cardiac Operations in Patients at
High Risk of Bleeding. Ann Thorac Surg . 2019;108(1):45-51.
doi:10.1016/j.athoracsur.2018.12.032
41. Ranucci M, Bozzetti G, Ditta A, Cotza M, Carboni G, Ballotta A, et
al. Surgical Reexploration After Cardiac Operations : Why a Worse
Outcome ? Ann Thorac Surg . 2008;86(5):1557-1562.
doi:10.1016/j.athoracsur.2008.07.114
42. Fröjd V, Jeppsson A. Reexploration for Bleeding and Its Association
With Mortality After Cardiac Surgery. Ann Thorac Surg .
2016;102(1):109-117. doi:10.1016/j.athoracsur.2016.01.006
43. Mehta R, Sheng S, O’Brien S, Grover F, Gammie J, Ferguson T, et al.
Reoperation for bleeding in patients undergoing coronary artery bypass
surgery: incidence, risk factors, time trends, and outcomes. Circ
Cardiovasc Qual Outcomes . 2009;2(6):583-590.
44. Biancari F, Airaksinen KEJ, Lip GYH. Benefits and risks of using
clopidogrel before coronary artery bypass surgery: Systematic review and
meta-analysis of randomized trials and observational studies. J
Thorac Cardiovasc Surg . 2012;143(3):665-675.e4.
doi:10.1016/j.jtcvs.2011.01.069
45. Mannacio V, Meier P, Antignano A, Di Tommaso L, De Amicis V, Vosa C.
Individualized strategy for clopidogrel suspension in patients
undergoing off-pump coronary surgery for acute coronary syndrome: A
case-control study. J Thorac Cardiovasc Surg .
2014;148(4):1299-1306. doi:10.1016/j.jtcvs.2013.12.011
46. Stone GW, Clayton TC, Mehran R, Dangas G, Parise H, Fahy M. Impact
of major bleeding and blood transfusions after cardiac surgery :
Analysis from the Acute Catheterization and Urgent Intervention Triage
strategY (ACUITY) trial. Am Heart J . 2012;163(3):522-529.
doi:10.1016/j.ahj.2011.11.016
47. Kapetanakis EI, Medlam DA, Boyce SW, Haile E, Hill PC, Dullum MKC,
et al. Clopidogrel administration prior to coronary artery bypass
grafting surgery: The cardiologist’s panacea or the surgeon’s headache?Eur Heart J . 2005;26(6):576-583. doi:10.1093/eurheartj/ehi074
48. Ferraris VA, Brown JR, Despotis GJ, Hammon JW, Reece TB, Saha SP, et
al. 2011 Update to The Society of Thoracic Surgeons and the Society of
Cardiovascular Anesthesiologists Blood Conservation Clinical Practice
Guidelines * The Society of Thoracic Surgeons Blood Conservat. Ann
Thorac Surg . 2011;91(3):944-982. doi:10.1016/j.athoracsur.2010.11.078
49. Valeri C, Khabbaz K, Sf K, Marquardt C, Ragno G, Feingold H, et al.
Effect of skin temperature on platelet function in patients undergoing
extracorporeal bypass. J Thorac Cardiovasc Surg .
1992;104(1):108-116.
50. Despotis GJ, Avidan MS, Hogue CW. Mechanisms and Attenuation of
Hemostatic Activation During Extracorporeal Circulation. Ann
Thorac Surg . 2001;72(5):S1821-31.
51. Levy JH. Discontinuation and management of direct-acting
anticoagulants for. Am J Emerg Med . 2019;34(11):14-18.
doi:10.1016/j.ajem.2016.09.048
52. Badhwar V, Rankin JS, Damiano RJ, Gillinov AM, Bakaeen FG, Edgerton
JR, et al. The Society of Thoracic Surgeons 2017 Clinical Practice
Guidelines for the Surgical Treatment of Atrial Fibrillation. Ann
Thorac Surg . 2017;103(1):329-341. doi:10.1016/j.athoracsur.2016.10.076